The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

In ex vivo primary cell models, the authors demonstrated that p300 KAT inhibition by KB-7898 modulated proinflammatory ...

Investigators were seeking a greater understanding of risk factors for hidradenitis suppurativa, a chronic inflammatory skin ...

Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for ...

SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device ...

Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at Texas A&M University College of Medicine. Alzheimer's is the most common form of ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

The concept of permanent and irreversible cell cycle arrest (senescence) was initially regarded as a defence mechanism against tumour progression. However, research has demonstrated that senescent ...

Department of Physiology, Harold Hamm Diabetes Center, The University of Oklahoma Health Science Center, Oklahoma City, United States ...

Detailed price information for Seastar Medical Hldg Corp (ICU-Q) from The Globe and Mail including charting and trades.

The SCD is a patented cell-directed extracorporeal device that employs immunomodulating technology to selectively target proinflammatory neutrophils and monocytes during CRRT. Unlike pathogen removal ...